[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594953":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":27,"locations":37,"responsibleParty":54,"collaborators":21,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":21,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":21,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":21,"overallStatus":40,"whyStopped":21,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1","EXPERIMENTAL","Radiotherapy and Apatinib and Camrelizumab and S-1 and Oxaliplatin",[13,14],"Drug: Apatinib+Camrelizumab+SOX","Radiation: Preoperative Radiotherapy",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Apatinib+Camrelizumab+SOX","Apatinib 250mg+Camrelizumab 200mg +S-1, Oxaliplatin, q3w",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"RADIATION","Preoperative Radiotherapy","Radiotherapy was administered using IMPT or IMRT. The target volume includes the gastric lesion, and regional lymph nodes. A regimen of 41.4 Gy in 23 fractions is preferred.",[9],[28,34],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Shu-Bei Wang, MD","CONTACT","+86-021-64370045","602400","wangshubei@163.com",{"name":35,"role":30,"phone":31,"phoneExt":32,"email":36},"Gang Cai, MD","cg11855@rjh.com.cn",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Ruijin Hospital, Shanghai Jiaotong University School of Medicine","RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":47,"coordinates":48},"Point",[49,50],121.45806,31.22222,{"lat":50,"lon":49},[53],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},{"type":55,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100594953","phase-2-perioperative-treatment-of-combined-radiotherapy-with-sox-apatinib-and-camrelizumab-for-oesophagogastric-cancer-100594953",false,"NCT07026149","Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer","Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Resectable Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: A Phase II Trial","Inclusion Criteria:\n\n* Has previously untreated localized gastric or GEJ adenocarcinoma as defined by T3-4N+M0;\n* Plans to proceed to surgery following pre-operative chemotherapy. Has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.\n* Has adequate organ function.\n* Male participants of childbearing potential must agree to use an adequate method of contraception for the course of the study through 120 days after the last dose of therapy.\n* Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of therapy.\n* Has life expectancy of greater than 12 months.\n\nExclusion Criteria:\n\n* Uncontrolled hypertension ( systolic ≥140 mmHg or diastolic ≥90 mmHg despite antihypertensive therapy)\n* Known hypersensitivity to any of the study drugs or excipients.\n* Known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs, coagulation disorders, thrombocytopenia, etc.);\n* Congenital or acquired immune deficiency (e.g. HIV infected)","ALL","18 Years","75 Years",{"count":67,"type":68},30,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","The study is being conducted to evaluate the efficacy, safety and tolerability of radiotherapy and chemotherapy, apatinib with camrelizumab in the neoadjuvant (prior to surgery) and adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.",[74],"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","2025-06-10",{"date":77,"type":78},"2025-06-18","ACTUAL",{"date":80,"type":68},"2025-06-08",{"date":82,"type":68},"2030-05-31",{"name":5,"class":6},1]